ALBUMIN (HUMAN)- albumin human solution
Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ALBUMIN (HUMAN) 5% safely and effectively. See full prescribing information for ALBUMIN (HUMAN) 5%.

ALBUMIN (HUMAN) 5%
For intravenous use only
5% solution
Initial U.S. Approval: 2006

INDICATIONS AND USAGE
• ALBUMIN (HUMAN) 5% is indicated for the restoration and maintenance of circulating blood volume for:
  (1)
• Hypovolemia. (1.1) (1)
• Hypoalbuminemia. (1.2) (1)
• Prevention of central volume depletion after paracentesis due to cirrhotic ascites. (1.3) (1)

DOSAGE AND ADMINISTRATION
• Intravenous use only. (2)
• Daily dose should not exceed 2 g per kg body weight. (2.1) (2)

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypovolemia (2)</td>
<td>Adults: 25 g (2.1)</td>
</tr>
<tr>
<td></td>
<td>Children: (less than 13 years) 2.5 to 1.25 g (2.1) (2)</td>
</tr>
<tr>
<td>Hypoalbuminemia (2)</td>
<td>Adults: 50 to 75 g (2.1)</td>
</tr>
</tbody>
</table>

Prevention of volume depletion after paracentesis (2) Adults: 8 g for every 1,000 mL of ascitic fluid removed (2.1) (2)

• Do not dilute with sterile water for injection as this may cause hemolysis in recipients. (5.6) (2)
• Store protected from light. (16) (2)
• Do not freeze. (16) (2)
• If large volumes (greater than 1500 ml) are administered, warm the product to room temperature before use. (2.2) (2)

DOSAGE FORMS AND STRENGTHS
• 5.0 g in 100 mL infusion bottle (3) (3)
• 12.5 g in 250 mL infusion bottle (3) (3)
• 25.0 g in 500 mL infusion bottle (3) (3)

CONTRAINDICATIONS
• Do not use in individuals who are hypersensitive to albumin preparations, any ingredient in the formulation, or components of the container. (4) (4)

WARNINGS AND PRECAUTIONS
• Hypersensitivity or allergic reactions have been observed, and may in some cases progress to severe anaphylaxis. Epinephrine should be available immediately to treat any acute hypersensitivity reaction. (5.1) (5)
• Hypervolemia: Use with caution in patients who are at risk of hypervolemia or hemodilution. Stop infusion if signs of cardiovascular overload occur. (5.2) (5)
• Electrolyte imbalances have been observed. Monitor electrolyte status. (5.3) (5)
• Ensure adequate substitution of other blood constituents. Monitor coagulation status and hematocrit. (5.4) (5)
• Hypotension has been observed. Monitor hemodynamic performance. (5.5) (5)
• Do not dilute solution with sterile water for injection. (5.6) (5)
• This product is made from human plasma and may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease agent. (5.7) (5)

ADVERSE REACTIONS
Most common adverse reactions seen in clinical trials (greater than or equal to 5% incidence) were anaphylactoid type reactions. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Octapharma USA Inc. at phone # 866-766-4860 and/or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (6)

USE IN SPECIFIC POPULATIONS
• Pregnancy: No human or animal data. Use only if needed. (8.1) (8)
• Pediatric use: The product should only be administered to pediatric patients if needed. (8.4) (8)

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1.1 Hypovolemia
1.2 Hypoalbuminemia
1.3 Prevention of Central Volume Depletion after Paracentesis due to Cirrhotic Ascites (Treatment Adjunct)

2 DOSAGE AND ADMINISTRATION

2.1 Dosage

2.2 Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity

5.2 Hypervolemia/Hemodilution

5.3 Electrolyte Imbalance

5.4 Coagulation Abnormalities

5.5 Laboratory Monitoring

5.6 Application Precautions

5.7 Infection Risk from Human Plasma

6 ADVERSE REACTIONS

6.1 General

6.2 Clinical Studies Experience

6.3 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Labor and Delivery

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

13 NON-CLINICAL TOXICOLOGY

14 CLINICAL STUDIES

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

17.1 Information for Patients

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Hypovolemia

ALBUMIN (HUMAN) 5% is indicated in the emergency treatment of hypovolemia with or without shock. Its effectiveness in reversing hypovolemia depends largely upon its ability to draw interstitial fluid into the circulation. It is most effective in patients who are well hydrated. When blood volume deficit is the result of hemorrhage, compatible red blood cells or whole blood should be administered as quickly as possible. [1, 2]

ALBUMIN (HUMAN) 5% should be used when hydration is not adequate. When hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 20% - 25% albumin solutions should be used. [1]

1.2 Hypoalbuminemia

For subjects with hypoalbuminemia who are critically ill and/or are bleeding actively, ALBUMIN (HUMAN) 5% infusions may be indicated. [3] When albumin deficit is the result of excessive protein loss, the effect of administration of ALBUMIN (HUMAN) 5% will be temporary unless the underlying disorder is reversed.

1.3 Prevention of Central Volume Depletion after Paracentesis due to Cirrhotic Ascites (Treatment Adjunct)

ALBUMIN (HUMAN) 5% may be used to maintain cardiovascular function following the removal of large volumes of ascitic fluid after paracentesis due to cirrhotic ascites. [2]

2 DOSAGE AND ADMINISTRATION

2.1 Dosage
**General Recommendations**

The concentration of the albumin preparation, dosage and the infusion rate should be adjusted to the patient’s individual requirements.

The dose required depends on the body weight of the patient, the severity of trauma or illness and on continuing fluid and protein losses. Measures of adequacy of circulating volume and not plasma albumin levels should be used to determine the dose required. The daily dose should not exceed 2 g of ALBUMIN (HUMAN) 5% per kg of body weight.

**Hypovolemia**

In adults, an intravenous infusion of 25 g of ALBUMIN (HUMAN) 5% should be given. If adequate response (stabilization of circulation) is not achieved within 15 to 30 minutes, an additional dose may be given.

In spite of limited information about the efficacy in pediatric subjects, an intravenous infusion of 2.5 to 12.5 g or 0.5 to 1 g/kg body weight may be given. If adequate response (stabilization of circulation) is not achieved within 15 to 30 minutes, an additional dose may be given.

Hemodilution may follow administration of ALBUMIN (HUMAN) 5%. If hemorrhage has occurred, this may result in relative anemia. This condition should be controlled by the supplemental administration of compatible red blood cells or compatible whole blood.

**Hypoalbuminemia**

In adults, intravenous infusion of 50 to 75 g of ALBUMIN (HUMAN) 5% may be used. Hypoalbuminemia is usually accompanied by a hidden extravascular albumin deficiency of equal magnitude. This total body albumin deficit must be considered when determining the amount of albumin necessary to reverse the hypoalbuminemia.

In burns, therapy usually starts with the administration of large volumes of crystalloid injection to maintain plasma volume. After 24 hours, ALBUMIN (HUMAN) 5% may be added at an initial dose of 25 g with the dose adjusted thereafter to maintain a plasma protein concentration of 2.5 g per 100 mL or a serum protein concentration of 5.2 g/100 mL.

**Prevention of Central Volume Depletion after Paracentesis due to Cirrhotic Ascites**

In adults, intravenous infusion of 8 g of ALBUMIN (HUMAN) 5% may be given for every 1,000 mL of ascitic fluid removed.

**2.2 Administration**

Intravenous use only.

Prior to administration, parenteral drug products should be inspected visually for turbidity and discoloration, whenever solution and container permit.

Do not dilute with sterile water for injection.

Do not use solutions of ALBUMIN (HUMAN) 5% which are cloudy or have deposits. Once the infusion container has been opened the contents should be used immediately. Discard the unused portion. Filtration of ALBUMIN (HUMAN) 5% is not required.

The infusion rate should be adjusted according to the individual circumstances and the indication. In plasma exchange during paracentesis, the infusion rate may be higher and should be adjusted to the rate of removal.

If large volumes (greater than 1500 ml) are administered, the product should be warmed to room temperature before use.

**3 DOSAGE FORMS AND STRENGTHS**

ALBUMIN (HUMAN) 5% is supplied in
- 5.0 g in 100 mL infusion bottle
- 12.5 g in 250 mL infusion bottle
- 25.0 g in 500 mL infusion bottle

**4 CONTRAINDICATIONS**

Do not use in individuals who are hypersensitive to albumin preparations, any ingredient in the formulation, or components of the container.

**5 WARNINGS AND PRECAUTIONS**

**5.1 Hypersensitivity**

Hypersensitivity or allergic reactions have been observed, and may in some cases progress to severe anaphylaxis. Epinephrine should be available immediately to treat any acute hypersensitivity reaction.

**5.2 Hypervolemia/Hemodilution**
Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the patient’s volume status. At the first clinical signs of possible cardiovascular overload, e.g., headache, dyspnea, increased blood pressure, jugular venous distention, elevated central venous pressure, pulmonary edema, the infusion should be stopped immediately and the patient reevaluated. Albumin should be used with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk for the patient. Examples of such conditions are:

- Decompensated cardiac insufficiency
- Hypertension
- Esophageal varices
- Pulmonary edema
- Hemorrhagic diathesis
- Severe anemia
- Renal and post-renal anuria.

5.3 Electrolyte Imbalance
When albumin is given, monitor the electrolyte status of the patient and take appropriate steps to restore or maintain the electrolyte balance.

5.4 Coagulation Abnormalities
If comparatively large volumes are to be replaced, monitoring of coagulation and hematocrit is necessary. Ensure adequate substitution of other blood constituents (coagulation factors, electrolytes, platelets and erythrocytes).

5.5 Laboratory Monitoring
If ALBUMIN (HUMAN) 5% is to be administered, monitor hemodynamic performance regularly; this may include:

- Arterial blood pressure and pulse rate
- Central venous pressure
- Pulmonary artery occlusion pressure
- Urine output
- Electrolytes
- Hematocrit/hemoglobin.

5.6 Application Precautions
ALBUMIN (HUMAN) 5% must not be diluted with sterile water for injection as this may cause hemolysis in recipients.

5.7 Infection Risk from Human Plasma
This product is a derivative of human plasma. Based on effective donor screening and product manufacturing processes it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob Disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have been identified for ALBUMIN (HUMAN) 5%.

6 ADVERSE REACTIONS

6.1 General
The most serious events are anaphylactic shock, circulatory failure, cardiac failure, and pulmonary edema.

The most common adverse events are anaphylactoid type of reactions.

Adverse reactions for ALBUMIN (HUMAN) 5% normally resolve when the infusion rate is slowed down or the infusion is stopped. In case of severe reactions, the infusion should be stopped and appropriate treatment should be initiated.

6.2 Clinical Studies Experience
No clinical studies were done using ALBUMIN (HUMAN) 5%.

6.3 Postmarketing Experience
The following adverse reactions have been identified during post-approval use of ALBUMIN (HUMAN) (any strength). Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency.

Table 1  Adverse reactions observed for ALBUMIN HUMAN (any strength) during post-marketing phase (in decreasing order of severity)

| Observed Adverse Reactions |
anaphylactic shock

hypersensitivity

congestive heart failure

circulatory failure

urticaria

angioneurotic edema

rash erythematous

confusional state

headache

chills

pyrexia

flushing

nausea

pruritus

hyperhidrosis

7 DRUG INTERACTIONS

No drug interaction studies have been conducted.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. Animal reproduction studies have not been performed with ALBUMIN (HUMAN) 5%. It is also not known whether ALBUMIN (HUMAN) 5% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. ALBUMIN (HUMAN) 5% should be given to a pregnant woman only if necessary.

8.2 Labor and Delivery

It is also not known whether ALBUMIN (HUMAN) 5% can cause fetal harm when administered to a woman during labor or delivery or if it will affect reproductive capacity. ALBUMIN (HUMAN) 5% should be given during labor or delivery only if necessary.

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. ALBUMIN (HUMAN) 5% should be given to nursing mothers only if necessary. Because many drugs are excreted in human milk, caution should be exercised when ALBUMIN (HUMAN) 5% is administered to a lactating woman.

8.4 Pediatric Use

Data on the use of ALBUMIN (HUMAN) 5% in children including premature babies are very limited. The product should be administered to pediatric patients only if needed.

8.5 Geriatric Use

Clinical studies did not include a sufficient number of subjects aged 65 and older to determine whether they respond differently from younger subjects.

11 DESCRIPTION

ALBUMIN (HUMAN) 5% is a sterile, liquid preparation of albumin derived from large pools of human plasma. All units of human plasma used in the manufacture of ALBUMIN (HUMAN) 5% are provided by FDA approved blood establishments only.

The product is manufactured by cold ethanol fractionation followed by ultra- and diafiltration. The manufacturing process includes final container pasteurization and additional bulk pasteurization at 60 +/- 0.5°C for 10 – 11 hours. The ALBUMIN (HUMAN) 5% manufacturing process provides a significant viral reduction in in vitro studies (table 2). These reductions are achieved through a combination of process steps including Cohn fractionation and final container pasteurization.

No procedure, however, has been shown to be completely effective in removing viral infectivity from
derivatives of human plasma. [see Warnings and Precautions, Infection Risk from Human Plasma (5.7)]

Table 2 In vitro reduction factor during ALBUMIN (HUMAN) 5% manufacturing

<table>
<thead>
<tr>
<th>Production step</th>
<th>Enveloped viruses</th>
<th>Non-enveloped viruses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PRV</td>
<td>SBV</td>
</tr>
<tr>
<td>Precipitation of Fraction I+II+III</td>
<td>3.53</td>
<td>5.89</td>
</tr>
<tr>
<td>Pasteurization final container</td>
<td>&gt; 8.07</td>
<td>&gt; 8.67</td>
</tr>
<tr>
<td>Global reduction factor</td>
<td>&gt; 11.60</td>
<td>&gt; 14.56</td>
</tr>
</tbody>
</table>

PRV: Pseudorabies Virus
SBV: Sindbis Virus
HIV-1: Human Immunodeficiency Virus - 1
Reo 3: Reovirus Type 3
PPV: Porcine Parvovirus
HAV: Hepatitis A Virus

ALBUMIN (HUMAN) 5% is a clear, slightly viscous liquid; it is almost colorless or slightly yellow or green.

The composition of ALBUMIN (HUMAN) 5% is as follows:

<table>
<thead>
<tr>
<th>Component</th>
<th>Quantity/1000 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein, of which greater than or equal to</td>
<td></td>
</tr>
<tr>
<td>96% is human albumin</td>
<td>50 g</td>
</tr>
<tr>
<td>Sodium</td>
<td>130 – 160 mmol</td>
</tr>
<tr>
<td>Potassium</td>
<td>less than or equal to 2 mmol</td>
</tr>
<tr>
<td>N-acetyl-DL-tryptophan</td>
<td>0.064 - 0.096 mmol/g protein</td>
</tr>
<tr>
<td>Caprylic acid</td>
<td>0.064 - 0.096 mmol/g protein</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>ad. 1000 ml</td>
</tr>
</tbody>
</table>

ALBUMIN (HUMAN) 5% contains no preservatives and components used in its packaging are latex-free.

12 CLINICAL PHARMACOLOGY

No pharmacokinetic or pharmacodynamic studies with ALBUMIN (HUMAN) 5% have been conducted.

12.1 Mechanism of Action

Albumin is responsible for 75-80% of the colloid osmotic pressure of normal plasma. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. [3]

Albumin is a protein with a total extravascular mass of approximately 160 g and an intravascular mass of about 120 g. [3]

12.2 Pharmacodynamics

Albumin (Human) 5% is approximately isotonic and iso-oncotic with normal human plasma. When treating patients with diminished blood volume, the effect of infused albumin may persist for many hours. The hemodilution lasts for a shorter time when albumin is administered to individuals with normal blood volume. [4]

13 NON-CLINICAL TOXICOLOGY

No non-clinical toxicology studies with ALBUMIN (HUMAN) 5% have been conducted. Human Albumin is a normal constituent of human plasma and acts like physiological albumin.

14 CLINICAL STUDIES
No clinical studies with ALBUMIN (HUMAN) 5% have been conducted.

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING
ALBUMIN (HUMAN) 5% is supplied in 5.0 g in 100 mL, 12.5 g in 250 mL or 25.0 g in 500 mL single use bottles.

<table>
<thead>
<tr>
<th>NDC Number</th>
<th>NDC Number</th>
<th>Size</th>
<th>Grams protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octapharma Pharmaeutika Produktionsges.m.b.H Octapharma AB</td>
<td>68209-623-01</td>
<td>100 ml</td>
<td>5.0</td>
</tr>
<tr>
<td>67467-623-02</td>
<td>68209-623-02</td>
<td>250 ml</td>
<td>12.5</td>
</tr>
<tr>
<td>67467-623-03</td>
<td>68209-623-03</td>
<td>500 ml</td>
<td>25.0</td>
</tr>
</tbody>
</table>

ALBUMIN (HUMAN) 5% may be stored for 36 months at +2°C to + 25°C (36°F to 77°F) from the date of manufacture.
Store protected from light.
Do not freeze.
Do not use after expiration date.
Do not use if turbid.

17 PATIENT COUNSELING INFORMATION
17.1 Information for Patients
This product is usually given in a hospital setting.
Inform patients being treated with Albumin (Human) 5% about the potential risks and benefits with its use [see Adverse Reactions (6)]. Discontinue immediately if allergic symptoms occur (e.g. skin rashes, hives, itching, breathing difficulties, coughing, nausea, vomiting, fall in blood pressure, increased heart rate).
Inform patients that ALBUMIN (HUMAN) 5% is a derivative of human plasma and may contain infectious agents that cause disease (e.g., viruses, and theoretically, CJD agent). Inform patients that the risk that ALBUMIN (HUMAN) 5% may transmit an infectious agent has been reduced by screening plasma donors for prior exposure for certain viruses, by testing the donated plasma for certain virus infections and by inactivating and/or removing certain viruses during manufacturing [see Warnings and Precautions (5.7)].

Manufactured by:
Octapharma Pharmaeutika Produktionsges.m.b.H.
Oberlaarer Strasse 235
A-1100 Vienna, Austria

Octapharma AB
Elersvägen 40
SE- 112 75, Sweden

U.S. License No. 1646

Distributed by:
Octapharma USA Inc.
121 River Street, 12th floor
PACKAGE LABEL - PRINCIPAL DISPLAY PANEL

Albumin (Human) 5%
5 g in 100 mL

Octapharma Pharmazeutika Produktionsges.m.b.H
NDC 67467-623-01

PACKAGE LABEL - PRINCIPAL DISPLAY PANEL

Albumin (Human) 5%
12.5 g in 250 mL

Octapharma Pharmazeutika Produktionsges.m.b.H
NDC 67467-623-02

PACKAGE LABEL - PRINCIPAL DISPLAY PANEL

Albumin (Human) 5%
25 g in 500 mL

Octapharma Pharmazeutika Produktionsges.m.b.H
NDC 67467-623-03

### ALBUMIN (HUMAN)
albumin human solution

#### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:67467-623</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Route of Administration

*Intravenous*

#### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALBUMIN (HUMAN)</td>
<td>(UNII: ZIF514RVZR)</td>
<td>50 g in 1000 mL</td>
</tr>
</tbody>
</table>

#### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:67467-623-03</td>
<td>500 mL in 1 BOTTLE, GLASS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:67467-623-02</td>
<td>250 mL in 1 BOTTLE, GLASS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:67467-623-01</td>
<td>100 mL in 1 BOTTLE, GLASS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLA</td>
<td>BLA125154</td>
<td>10/17/2006</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Octapharma Pharmazeutika Produktionsgesellschaft m.b.H. (301119178)

Revised: 8/2008

Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.